Jazz Pharmaceuticals Plc Aktie News

Jazz Pharmaceuticals plc surged over 20% after positive Phase 3 data for Ziihera in HER2+ gastroesophageal cancer. JAZZ's diversified portfolio, strong Q3 earnings, and upgraded 2025 revenue guidance support its current double-digit billion valuation. Key risks include upcoming patent expiries, new competition for Xywav, and uncertainty around long-term profitability and revenue replacement.

Jazz Pharmaceuticals plc and Zymeworks Inc. announced positive topline phase 3 results for Ziihera in HER2-positive gastroesophageal adenocarcinoma. Ziihera in combination with chemotherapy and in combination with Tevimbra and chemotherapy outperformed trastuzumab plus chemotherapy, and the triple combination achieved statistically significant overall survival benefit. The GEA indication repres...

Shares of Jazz Pharmaceuticals and Zymeworks catapulted Monday after the duo unveiled positive test results for a gastric cancer drug.

The companies' drug Ziihera shows clinically meaningful benefits for patients with gastroesophageal adenocarcinoma.

Ziihera plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend toward statistical significance for OS at the first OS interim analysis Ziihera plus the PD-1 inhibitor Tevimbra ® (tislelizumab) and chemotherapy demonstrated clinically meaningful and statistically...

Data highlight continued progress in Jazz's brain tumor research and demonstrate the company's commitment to advancing treatment options for patients with rare and aggressive brain tumors For U.S. media and investors only DUBLIN , Nov. 11, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will present five abstracts at the 2025 Society for Neuro-Oncol...

Jazz Pharmaceuticals plc ( JAZZ ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Jack Spinks - Executive Director of Investor Relations Renée Galá - President, CEO & Director Samantha Pearce - Executive VP & Chief Commercial Officer Robert Iannone - Executive VP, Chief Medical Officer and Global Head of Research & Development Philip Johnson - Executive VP & CFO Conferen...

– Modeyso™ approved as the first and only treatment for recurrent H3 K27M-mutant DMG – – Zepzelca ® and atezolizumab (Tecentriq ® ) combination approved as maintenance therapy in 1L ES-SCLC – – 3Q25 total revenues increased 7% year-over-year driven by robust growth of Epidiolex ® , Xywav ® and the launch of Modeyso – DUBLIN , Nov. 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ...